NRG-GY012

Clinical Trial Title A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
Trial Status Open to Enrollment
Start Date 11/02/2018
Location Doctors & Locations
Trial Type Cancer - Adult Oncology
Specific Condition Endometrial Cancer
Description This phase II trial studies how well olaparib and cediranib maleate work in treating patients with endometrial cancer that has come back, does not respond to treatment, or has spread to other places in the body. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Eligibility Criteria

Eligibility Criteria

  • Patients must have recurrent or persistent endometrial carcinoma, which is refractory to curative therapy or established treatments.
  • Patients must have measurable disease as defined by RECIST 1.1 or non-measurable (detectable) disease.
  • Patients must have had one prior chemotherapeutic regimen for management of endometrial carcinoma.
  • Patients may have received non cytotoxic therapy including immunotherapy but excluding cediranib and olaparib for management of recurrent or persistent disease.
  • Patients must have an ECOG Performance Status of 0, 1 or 2 (Karnofsky ≥ 60%) within 7 days prior to registration

Please contact Legacy Oncology Research for additional study inclusion/exclusion information. 

 

 

 
IRB Number Central IRB
Notes https://clinicaltrials.gov/ct2/show/NCT03660826?term=nrg-gy012
Principal Investigator Colleen McCormick, MD
Contact Name Oncology Clinical Research
Contact Phone 503-413-8199
Contact Fax 503-413-6920
Contact E-Mail oncologyresearch@lhs.org